Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis

Study identifier:ALXN1720-MG-301

ClinicalTrials.gov identifier:NCT05556096

EudraCT identifier:2022-000460-21

CTIS identifier:N/A

Recruiting

Official Title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis

Medical condition

Generalized Myasthenia Gravis

Phase

Phase 3

Healthy volunteers

No

Study drug

ALXN1720, Placebo

Sex

All

Estimated Enrollment

254

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 21 Nov 2022
Estimated Primary Completion Date: 05 Aug 2025
Estimated Study Completion Date: 07 Jul 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by Alexion Pharmaceuticals, Inc.

Sponsors

Alexion Pharmaceuticals, Inc.

Collaborators

-

Inclusion and exclusion criteria